3-(azepan-1-yl)-2-[1-cyano-2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-N-[3-(dimethylamino)propyl]quinoxaline-6-carboxamide | 1425050-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(azepan-1-yl)-2-[1-cyano-2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-N-[3-(dimethylamino)propyl]quinoxaline-6-carboxamide
• CAS: 1425050-98-1
• 化学式: C₃₁H₃₉N₇O₃
• 分子量: 557.696
• InChiKey: UCDIIIWKKFTQAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-甲氧基苄胺 在 potassium tert-butylate 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 7.0h， 生成 3-(azepan-1-yl)-2-[1-cyano-2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-N-[3-(dimethylamino)propyl]quinoxaline-6-carboxamide
  参考文献：
  名称：

  Discovery and structure–activity relationships of small molecules that block the human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein–protein interaction

  摘要：

  The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.014

文献信息

• Discovery and structure–activity relationships of small molecules that block the human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein–protein interaction
  作者：Zhaolin Wang、Cara Fraley、Adam R. Mezo

  DOI：10.1016/j.bmcl.2013.01.014

  日期：2013.3

  The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen. (c) 2013 Elsevier Ltd. All rights reserved.